The combination of TRAIL receptor (DR5)-targeted therapy and BBR treatment was demonstrated to effectively inhibit primary tumor growth and metastatic spread in the murine 4T1 breast cancer model. This evidence concerns the gene TNFRSF10B and breast carcinoma.